Berlin-based company Cara Care has announced the closing of a $7 million financing round led by international food and nutrition producer Dr. Schär AG, which also involved existing investors Sabadell Asabys and Johnson & Johnson Innovation - JJDC, Inc, who led the Series A financing round. The investment lays the foundation for the international growth of Cara Care’s digital gastrointestinal therapeutics.
"Sabadell Assabys is very proud to welcome Dr. Schär to Cara Care. Awakening the interest of one of the main players in the special nutrition industry reinforces our thesis about the company and shows how digital therapies can reach patients through various channels, leveraging the usability of technological tools, data management and clinical validation", says Guillem Masferrer, Director of Investments at Sabadell Assabys.
Cara Care was recently approved by the German Federal Institute for Drugs and Medical Devices as a prescribable digital therapeutic application (DiGA). Under the Digital Healthcare Act (DVG), all statutory health insurance companies assume the costs of DiGAs without additional payment from the patient: a model for integrating digital healthcare that many countries are watching closely. Cara Care also recently completed the rigorous ISO 27001 certification, a critical step in its secure data management and information security risk management efforts.
Photo: Josep Lluís Sanfeliu and Guillem Masferrer, Asabys Partners
Comments